Creative Planning
NDRM

Creative Planning’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Creative Planning’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$27K – 5112
2017
Q1 		$27K Buy
+1,000
New +$24.8K ﹤0.01% 2941

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Creative Planning's NDRM Position: Q2 2017 in Review

Creative Planning sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2017, closing a stake of 1,000 shares — an estimated $27K sold.

Creative Planning first reported a position in NDRM in Q1 2017 and held it in 1 quarter. The position peaked at $27K in Q1 2017. 73 funds tracked by Wall St. Rank hold NDRM as of Q2 2017.

  • Creative Planning reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Creative Planning sold 1,000 NeuroDerm Ltd. Ordinary Shares shares in Q2 2017, an estimated $27K.
  • Creative Planning first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 1 quarter.
  • Creative Planning's NeuroDerm Ltd. Ordinary Shares position peaked at $27K in Q1 2017.
  • 73 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.